NewsBenzingaAgomab Therapeutics在NOV-ERA全球2b期研究中为首位患者给药,该研究评估ontunisertib用于有症状FSCD患者 Agomab Therapeutics在NOV-ERA全球2b期研究中为首位患者给药,该研究评估ontunisertib用于有症状FSCD患者 Benzinga 2026.10.13 20:06 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Commercial Metals, Lowers Price Target to $63 Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings TD Cowen Maintains Hold on Calumet, Lowers Price Target to $37 If You Invested $100 In Cenovus Energy Stock 5 Years Ago, You Would Have This Much Today Wells Fargo Maintains Overweight on Cleveland-Cliffs, Raises Price Target to $18 TD Cowen Maintains Buy on BWX Technologies, Lowers Price Target to $180